Table 1.

PK model variables of gefitinib in plasma and tumor from LN229-wild-type EGFR and LN229-EGFRvIII mutant tumor-bearing athymic mice following 10 mg/kg i.v., 50 mg/kg i.a., or 150 mg/kg p.o. single-dose administrations

VariablesLN229-wild-type EGFR tumor-bearing groupLN229-EGFRvIII mutant tumor-bearing group
F0.45 (6.9)*0.52 (6.6)
K10 (h−1)0.85 (17.8)0.70 (12.5)
K12 (h−1)1.57 (21.6)0.93 (20.0)
K21 (h−1)0.41 (12.1)0.37 (11.4)
Ka (h−1)0.88 (14.6)0.82 (13.6)
Q (mL·h−1)4.5 (13.5)4.4 (10.8)
RI8.2 (7.3)9.8 (6.7)
Vc (mL)75.0 (19.5)103.8 (14.0)
Vt (mL)1.31.3
  • * Values represent mean (% coefficient of variation) of model fitted variables.